AN UNDETECTABLE PB MRD STATUS SHOULD BE THE THERAPEUTIC GOAL WITH VENETOCLAX THERAPY IN RELAPSED/ REFRACTORY CLL

Methods: 62 CLL patients treated with continuous Ven were serially monitored for MRD in PB and BM, using flow cytometry by ERIC methodology. Patients who came off Ven, including some in deep remission, were censored at time of cessation. Baseline factors assessed included variables in Table 1. Kaplan Meier and univariate analyses were done with significance set at P<0.05. Keywords: chronic lymphocytic leukemia (CLL); minimal residual disease...